Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis

Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuroimmunology Jg. 271; H. 1-2; S. 66 - 68
Hauptverfasser: Brown, J. William L., Martin, Peter J., Thorpe, John W., Michell, Andrew W., Coles, Alasdair J., Cox, Amanda L., Vincent, Angela, Zandi, Michael S.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Netherlands Elsevier B.V 15.06.2014
Schlagworte:
Adult
Aged
Allergy and Immunology
Antibodies - blood
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Autoantibody
Cognition
Encephalitis
Encephalitis - blood
Encephalitis - drug therapy
Encephalitis - immunology
Female
Humans
Immunologic Factors - therapeutic use
LGI1
Male
Neurology
Proteins - immunology
Rituximab
Secondary Prevention
Seizures - drug therapy
Treatment Outcome
VGKC
LGI1
Autoantibody
Rituximab
VGKC
Encephalitis
Cognition
ISSN:0165-5728, 1872-8421, 1872-8421
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic seizures (FBDS) and received rituximab after relapsing or refractory disease. Both cases achieved sustained clinical remission of up to 15 and 56months respectively. Rituximab use allowed withdrawal of corticosteroids and was well tolerated. Randomized clinical trials are needed in LGI1 encephalitis and other autoimmune encephalitides.
AbstractList Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic seizures (FBDS) and received rituximab after relapsing or refractory disease. Both cases achieved sustained clinical remission of up to 15 and 56 months respectively. Rituximab use allowed withdrawal of corticosteroids and was well tolerated. Randomized clinical trials are needed in LGI1 encephalitis and other autoimmune encephalitides.Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic seizures (FBDS) and received rituximab after relapsing or refractory disease. Both cases achieved sustained clinical remission of up to 15 and 56 months respectively. Rituximab use allowed withdrawal of corticosteroids and was well tolerated. Randomized clinical trials are needed in LGI1 encephalitis and other autoimmune encephalitides.
Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic seizures (FBDS) and received rituximab after relapsing or refractory disease. Both cases achieved sustained clinical remission of up to 15 and 56 months respectively. Rituximab use allowed withdrawal of corticosteroids and was well tolerated. Randomized clinical trials are needed in LGI1 encephalitis and other autoimmune encephalitides.
Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic seizures (FBDS) and received rituximab after relapsing or refractory disease. Both cases achieved sustained clinical remission of up to 15 and 56months respectively. Rituximab use allowed withdrawal of corticosteroids and was well tolerated. Randomized clinical trials are needed in LGI1 encephalitis and other autoimmune encephalitides.
Abstract Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic seizures (FBDS) and received rituximab after relapsing or refractory disease. Both cases achieved sustained clinical remission of up to 15 and 56 months respectively. Rituximab use allowed withdrawal of corticosteroids and was well tolerated. Randomized clinical trials are needed in LGI1 encephalitis and other autoimmune encephalitides.
Author Coles, Alasdair J.
Cox, Amanda L.
Brown, J. William L.
Martin, Peter J.
Vincent, Angela
Thorpe, John W.
Zandi, Michael S.
Michell, Andrew W.
Author_xml – sequence: 1
  givenname: J. William L.
  surname: Brown
  fullname: Brown, J. William L.
  email: william.brown@doctors.org.uk
  organization: Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom
– sequence: 2
  givenname: Peter J.
  surname: Martin
  fullname: Martin, Peter J.
  email: peter.martin@addenbrookes.nhs.uk
  organization: Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom
– sequence: 3
  givenname: John W.
  surname: Thorpe
  fullname: Thorpe, John W.
  email: john.thorpe@addenbrookes.nhs.uk
  organization: Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom
– sequence: 4
  givenname: Andrew W.
  surname: Michell
  fullname: Michell, Andrew W.
  email: andrew.michell@addenbrookes.nhs.uk
  organization: Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom
– sequence: 5
  givenname: Alasdair J.
  surname: Coles
  fullname: Coles, Alasdair J.
  email: ajc1020@medschl.cam.ac.uk
  organization: Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom
– sequence: 6
  givenname: Amanda L.
  surname: Cox
  fullname: Cox, Amanda L.
  email: amandacox1@nhs.net
  organization: Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom
– sequence: 7
  givenname: Angela
  surname: Vincent
  fullname: Vincent, Angela
  email: angela.vincent@ndcn.ox.ac.uk
  organization: Neurosciences Group, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom
– sequence: 8
  givenname: Michael S.
  orcidid: 0000-0002-9612-9401
  surname: Zandi
  fullname: Zandi, Michael S.
  email: msz20@cam.ac.uk
  organization: Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24703099$$D View this record in MEDLINE/PubMed
BookMark eNqNks1u1DAUhS1URKeFV6iyZJPUdpw_CSFQBQVpJBbA2nLsm84NiT3YTsu8PY6ms-mCsvLC3zn2PedekDPrLBByxWjBKKuvx2K0sHiHc8EpEwUtC8r4C7JhbcPzVnB2RjYJrPKq4e05uQhhpJRVpehekXMuGlrSrtuQ3dbZuzyCnzMPM4aAzmYPGHeZx7j8wVn1Gdp0N3ilo_OHbIJFo4Xco95ldxO6WSUiXeK9imAylikbsXfmkIHVsN-pCSOG1-TloKYAbx7PS_Lz86cfN1_y7bfbrzcft7kWTRvztup7w7q6o6ZUwvR9rZkeuOmbqtKlanttKKWiBBAtM6xhvVAwdEYkcqiEKS_J26Pv3rvfC4Qo01QapklZcEuQrOI1442oRUKvHtGln8HIvU_j-oM8pZOAd0dAexdCykBqjCqmiKJXOElG5VqGHOWpDLmWIWkpUxlJXj-Rn154VvjhKIQU1D2Cl0HjGqZBDzpK4_B5i_dPLPSEFrWafsEBwugWb1MNksnAJZXf11VZN4WJFG9Hy38b_M8P_gJXAdT6
CitedBy_id crossref_primary_10_3389_fneur_2019_00480
crossref_primary_10_1002_brb3_1793
crossref_primary_10_1136_practneurol_2018_001899
crossref_primary_10_1007_s00415_014_7473_x
crossref_primary_10_1016_j_spen_2014_08_001
crossref_primary_10_1212_WNL_0000000000010789
crossref_primary_10_1016_j_neurol_2021_12_001
crossref_primary_10_1016_j_clineuro_2022_107559
crossref_primary_10_1080_01676830_2022_2134429
crossref_primary_10_1097_ACI_0000000000000485
crossref_primary_10_1007_s13760_020_01336_z
crossref_primary_10_1016_j_jneuroim_2015_10_010
crossref_primary_10_1016_j_schres_2014_11_001
crossref_primary_10_1136_jnnp_2017_317780
crossref_primary_10_1002_ana_25120
crossref_primary_10_3389_fneur_2022_949240
crossref_primary_10_1038_s41582_020_0381_z
crossref_primary_10_3389_fneur_2022_741244
crossref_primary_10_1007_s40263_022_00943_z
crossref_primary_10_1016_j_genhosppsych_2025_02_016
crossref_primary_10_1176_appi_focus_20160019
crossref_primary_10_1097_WCO_0000000000001048
crossref_primary_10_1586_14737175_2015_1115720
crossref_primary_10_1016_j_seizure_2016_07_002
crossref_primary_10_1212_WNL_0000000000003009
crossref_primary_10_3389_fneur_2021_791014
Cites_doi 10.1146/annurev-med-070912-133235
10.1016/S1474-4422(12)70310-1
10.1136/jnnp.2009.178293
10.1093/brain/awt212
10.1136/jnnp.2009.174888
10.1093/brain/awh077
10.1002/art.22046
10.1016/j.jneuroim.2013.10.005
10.1093/brain/awq213
10.1002/art.20592
10.1093/brain/awt256
10.1056/NEJMoa032534
ContentType Journal Article
Copyright 2014 Elsevier B.V.
Elsevier B.V.
Copyright © 2014 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2014 Elsevier B.V.
– notice: Elsevier B.V.
– notice: Copyright © 2014 Elsevier B.V. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.jneuroim.2014.03.012
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1872-8421
EndPage 68
ExternalDocumentID 24703099
10_1016_j_jneuroim_2014_03_012
S0165572814000903
1_s2_0_S0165572814000903
Genre Journal Article
Case Reports
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1B1
1P~
1RT
1~.
1~5
4.4
457
4CK
4G.
5GY
5VS
7-5
71M
8P~
9JM
AAAJQ
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AARKO
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABFNM
ABFRF
ABIVO
ABJNI
ABMAC
ABMZM
ABTEW
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACLOT
ACRLP
ACVFH
ADBBV
ADCNI
ADEZE
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFPUW
AFRHN
AFTJW
AFXIZ
AGEKW
AGHFR
AGUBO
AGWIK
AGYEJ
AIEXJ
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
AXJTR
BKOJK
BLXMC
BNPGV
CJTIS
CNWQP
CS3
DU5
EBS
EFJIC
EFKBS
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HMO
HMQ
IHE
J1W
KOM
L7B
LUGTX
LX8
M29
M2V
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OP~
OZT
P-8
P-9
P2P
PC.
Q38
ROL
RPZ
SCC
SDF
SDG
SDP
SEL
SES
SPCBC
SSH
SSI
SSN
SSZ
T5K
UNMZH
Z5R
~G-
~HD
.GJ
29L
53G
AACTN
AAQXK
ABWVN
ACRPL
ADMUD
ADNMO
AFCTW
AFJKZ
AFKWA
AHHHB
AJOXV
AKRLJ
AMFUW
ASPBG
AVWKF
AZFZN
FEDTE
FGOYB
G-2
HDW
HMG
HMK
HVGLF
HZ~
R2-
RIG
SAE
SEW
SIN
SNS
WUQ
XJT
ZGI
AGCQF
9DU
AAYXX
AGQPQ
AIGII
APXCP
CITATION
AGRNS
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c478t-85bbd19690d3a4dbb6c1cf2db755c3a8bcd00043ee481d171b4aef9d4bb6f54d3
ISICitedReferencesCount 27
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000337207700011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0165-5728
1872-8421
IngestDate Wed Oct 01 14:39:35 EDT 2025
Mon Jul 21 06:01:33 EDT 2025
Tue Nov 18 22:15:57 EST 2025
Sat Nov 29 07:26:30 EST 2025
Thu Sep 18 02:46:30 EDT 2025
Sun Feb 23 10:19:10 EST 2025
Tue Oct 14 19:36:15 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1-2
Keywords LGI1
Autoantibody
Rituximab
VGKC
Encephalitis
Cognition
Language English
License Copyright © 2014 Elsevier B.V. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c478t-85bbd19690d3a4dbb6c1cf2db755c3a8bcd00043ee481d171b4aef9d4bb6f54d3
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ORCID 0000-0002-9612-9401
PMID 24703099
PQID 1526127464
PQPubID 23479
PageCount 3
ParticipantIDs proquest_miscellaneous_1526127464
pubmed_primary_24703099
crossref_citationtrail_10_1016_j_jneuroim_2014_03_012
crossref_primary_10_1016_j_jneuroim_2014_03_012
elsevier_sciencedirect_doi_10_1016_j_jneuroim_2014_03_012
elsevier_clinicalkeyesjournals_1_s2_0_S0165572814000903
elsevier_clinicalkey_doi_10_1016_j_jneuroim_2014_03_012
PublicationCentury 2000
PublicationDate 2014-06-15
PublicationDateYYYYMMDD 2014-06-15
PublicationDate_xml – month: 06
  year: 2014
  text: 2014-06-15
  day: 15
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Journal of neuroimmunology
PublicationTitleAlternate J Neuroimmunol
PublicationYear 2014
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Irani, Alexander, Waters, Kleopa, Pettingill, Zuliani, Peles, Buckley, Lang, Vincent (bb0020) 2010; 133
Zandi (bb0060) 2013; 136
Edwards, Szczepanski, Szechinski, Filipowicz-Sosnowska, Emery, Close, Stevens, Shaw (bb0010) 2004; 350
Irani, Stagg, Schott, Rosenthal, Schneider, Pettingill, Pettingill, Waters, Thomas, Voets, Cardoso, Cash, Manning, Lang, Smith, Vincent, Johnson (bb0025) 2013
Shin, Lee, Shin, Moon, Lim, Byun, Kim, Lee, Kim, Park, Jung, Lee, Chu (bb0035) 2013; 265
Wong, Saunders, Larner, Das, Hart (bb0055) 2010; 81
Vincent, Buckley, Schott, Baker, Dewar, Detert, Clover, Parkinson, Bien, Omer, Lang, Rossor, Palace (bb0050) 2004; 127
Faurschou, Jayne (bb0015) 2013; 65
Sadnicka, Reilly, Mummery, Brandner, Hirsch, Lunn (bb0030) 2011; 82
Anolik, Barnard, Cappione, Pugh-Bernard, Felgar, Looney, Sanz (bb0005) 2004; 50
Smith, Jones, Burns, Jayne (bb0040) 2006; 54
Titulaer, McCracken, Gabilondo, Armangue, Glaser, Iizuka, Honig, Benseler, Kawachi, Martinez-Hernandez, Aguilar, Gresa-Arribas, Ryan-Florance, Torrents, Saiz, Rosenfeld, Balice-Gordon, Graus, Dalmau (bb0045) 2013; 12
Faurschou (10.1016/j.jneuroim.2014.03.012_bb0015) 2013; 65
Vincent (10.1016/j.jneuroim.2014.03.012_bb0050) 2004; 127
Edwards (10.1016/j.jneuroim.2014.03.012_bb0010) 2004; 350
Irani (10.1016/j.jneuroim.2014.03.012_bb0020) 2010; 133
Shin (10.1016/j.jneuroim.2014.03.012_bb0035) 2013; 265
Sadnicka (10.1016/j.jneuroim.2014.03.012_bb0030) 2011; 82
Zandi (10.1016/j.jneuroim.2014.03.012_bb0060) 2013; 136
Wong (10.1016/j.jneuroim.2014.03.012_bb0055) 2010; 81
Smith (10.1016/j.jneuroim.2014.03.012_bb0040) 2006; 54
Titulaer (10.1016/j.jneuroim.2014.03.012_bb0045) 2013; 12
Irani (10.1016/j.jneuroim.2014.03.012_bb0025) 2013
Anolik (10.1016/j.jneuroim.2014.03.012_bb0005) 2004; 50
References_xml – volume: 12
  start-page: 157
  year: 2013
  end-page: 165
  ident: bb0045
  article-title: Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study
  publication-title: Lancet Neurol.
– volume: 82
  start-page: 230
  year: 2011
  end-page: 232
  ident: bb0030
  article-title: Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 265
  start-page: 75
  year: 2013
  end-page: 81
  ident: bb0035
  article-title: VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy
  publication-title: J. Neuroimmunol.
– volume: 65
  start-page: 263
  year: 2013
  end-page: 278
  ident: bb0015
  article-title: Anti-B cell antibody therapies for inflammatory rheumatic diseases
  publication-title: Annu. Rev. Med.
– year: 2013
  ident: bb0025
  article-title: Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype
  publication-title: Brain
– volume: 50
  start-page: 3580
  year: 2004
  end-page: 3590
  ident: bb0005
  article-title: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
  publication-title: Arthritis Rheum.
– volume: 54
  start-page: 2970
  year: 2006
  end-page: 2982
  ident: bb0040
  article-title: Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment
  publication-title: Arthritis Rheum.
– volume: 127
  start-page: 701
  year: 2004
  end-page: 712
  ident: bb0050
  article-title: Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis
  publication-title: Brain
– volume: 133
  start-page: 2734
  year: 2010
  end-page: 2748
  ident: bb0020
  article-title: Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia
  publication-title: Brain
– volume: 81
  start-page: 1167
  year: 2010
  end-page: 1169
  ident: bb0055
  article-title: An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 136
  start-page: 2933
  year: 2013
  end-page: 2935
  ident: bb0060
  article-title: Defining and treating leucine-rich glioma inactivated 1 antibody associated autoimmunity
  publication-title: Brain
– volume: 350
  start-page: 2572
  year: 2004
  end-page: 2581
  ident: bb0010
  article-title: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
  publication-title: N. Engl. J. Med.
– volume: 65
  start-page: 263
  year: 2013
  ident: 10.1016/j.jneuroim.2014.03.012_bb0015
  article-title: Anti-B cell antibody therapies for inflammatory rheumatic diseases
  publication-title: Annu. Rev. Med.
  doi: 10.1146/annurev-med-070912-133235
– volume: 12
  start-page: 157
  year: 2013
  ident: 10.1016/j.jneuroim.2014.03.012_bb0045
  article-title: Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(12)70310-1
– volume: 81
  start-page: 1167
  year: 2010
  ident: 10.1016/j.jneuroim.2014.03.012_bb0055
  article-title: An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis
  publication-title: J. Neurol. Neurosurg. Psychiatry
  doi: 10.1136/jnnp.2009.178293
– year: 2013
  ident: 10.1016/j.jneuroim.2014.03.012_bb0025
  article-title: Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype
  publication-title: Brain
  doi: 10.1093/brain/awt212
– volume: 82
  start-page: 230
  year: 2011
  ident: 10.1016/j.jneuroim.2014.03.012_bb0030
  article-title: Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis
  publication-title: J. Neurol. Neurosurg. Psychiatry
  doi: 10.1136/jnnp.2009.174888
– volume: 127
  start-page: 701
  year: 2004
  ident: 10.1016/j.jneuroim.2014.03.012_bb0050
  article-title: Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis
  publication-title: Brain
  doi: 10.1093/brain/awh077
– volume: 54
  start-page: 2970
  year: 2006
  ident: 10.1016/j.jneuroim.2014.03.012_bb0040
  article-title: Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.22046
– volume: 265
  start-page: 75
  year: 2013
  ident: 10.1016/j.jneuroim.2014.03.012_bb0035
  article-title: VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy
  publication-title: J. Neuroimmunol.
  doi: 10.1016/j.jneuroim.2013.10.005
– volume: 133
  start-page: 2734
  year: 2010
  ident: 10.1016/j.jneuroim.2014.03.012_bb0020
  article-title: Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia
  publication-title: Brain
  doi: 10.1093/brain/awq213
– volume: 50
  start-page: 3580
  year: 2004
  ident: 10.1016/j.jneuroim.2014.03.012_bb0005
  article-title: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.20592
– volume: 136
  start-page: 2933
  year: 2013
  ident: 10.1016/j.jneuroim.2014.03.012_bb0060
  article-title: Defining and treating leucine-rich glioma inactivated 1 antibody associated autoimmunity
  publication-title: Brain
  doi: 10.1093/brain/awt256
– volume: 350
  start-page: 2572
  year: 2004
  ident: 10.1016/j.jneuroim.2014.03.012_bb0010
  article-title: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa032534
SSID ssj0015349
Score 2.2479544
Snippet Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on...
Abstract Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 66
SubjectTerms Adult
Aged
Allergy and Immunology
Antibodies - blood
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Autoantibody
Cognition
Encephalitis
Encephalitis - blood
Encephalitis - drug therapy
Encephalitis - immunology
Female
Humans
Immunologic Factors - therapeutic use
LGI1
Male
Neurology
Proteins - immunology
Rituximab
Secondary Prevention
Seizures - drug therapy
Treatment Outcome
VGKC
Title Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0165572814000903
https://www.clinicalkey.es/playcontent/1-s2.0-S0165572814000903
https://dx.doi.org/10.1016/j.jneuroim.2014.03.012
https://www.ncbi.nlm.nih.gov/pubmed/24703099
https://www.proquest.com/docview/1526127464
Volume 271
WOSCitedRecordID wos000337207700011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals 2021
  customDbUrl:
  eissn: 1872-8421
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015349
  issn: 0165-5728
  databaseCode: AIEXJ
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6DiFeEGx8lI_JSIiXKqVJnNh5rNAQTGVCYkDfrDhx11RtUqXt1P1F_JucYzvNVCoGiJeoSuLa8v1yPp9_d4fQ60iElCQC9ia-8BzCgr4jYkXbYRLWhzSUtCKPfxvS83M2GkWfW60fNhbmakbznG020eK_ihrugbBV6OwfiLv-U7gBv0HocAWxw_VWgh8W-aWjFG63VLXclDdMe1vLbLXeZPNY6BiWcVmV2lGFI9bqdN0BjTjpXs6yYh6rPBxJVfgM7FG3C7OfiSK97io1sJgo0z1b7jFrqwSZmYo6ueGwr7f7Zz2bCaI77G394TaZQcUXhpcahJVyIS1puPt920RzWLekTPvMuDBcoqhWOohT-9V2Ymu0qzMMnICa0HGjqz1dr8WC0kROat0bho1VXNfq2VkftKti2puayVDcPlJluTVk7pu5t7-oQagxwDa0rzxaB-jQo0HE2uhw8PF0dFYfWAW-3mnZQTeC0X_d2z47aN8-p7J3Lh6g-0aieKAB9hC1ZH6Ejgd5vCrm1_gNrqjDlYiP0N1PhqFxjCY1_HANP6zgh2v44SzHW_jhJvywhh9uwA-72MIPN-H3CH19f3rx7oNjqnk4CaFs5bBAiFQlY-qnfkxSIcLETcZeKmgQJH7MRJJW59JSElASLnUFieU4Sgm8OQ5I6j9G7bzI5VOE2RisqlgyMDd9QseESRGlAvYycZ8RErodFNi55YlJda8qrsy45TROuZUJVzLhfZ-DTDrobd1uoZO9_LYFtaLjNpQZFl8OePu7lnJpVMmSu3zp8T7fwWAHRXVLYyZr8_dWvb6y-OKAAXU4GOeyWENvgUomSElIOuiJBl49Bx5RdkEUPfuHnp-je9tP_wVqr8q1fInuJFeAmPIEHdAROzEf1U8E__6o
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+remission+with+rituximab+in+refractory+leucine-rich+glioma+inactivated+1+antibody+encephalitis&rft.jtitle=Journal+of+neuroimmunology&rft.au=Brown%2C+J.+William+L.&rft.au=Martin%2C+Peter+J.&rft.au=Thorpe%2C+John+W.&rft.au=Michell%2C+Andrew+W.&rft.date=2014-06-15&rft.pub=Elsevier+B.V&rft.issn=0165-5728&rft.volume=271&rft.issue=1-2&rft.spage=66&rft.epage=68&rft_id=info:doi/10.1016%2Fj.jneuroim.2014.03.012&rft.externalDocID=S0165572814000903
thumbnail_m http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01655728%2FS0165572814X00068%2Fcov150h.gif